Table S1 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Autor: Brian I. Rini, M. Brent McHenry, Shruti Shally Saggi, Yuko Ishii, Andre M. Murad, Sumanta K. Pal, Jeronimo R. Rodriguez-Cid, Alain Ravaud, Judit Kocsis, Scott S. Tykodi, Philippe Barthélémy, Michael R. Harrison, Frede Donskov, Thomas Powles, Saby George, Osvaldo Arén Frontera, Miriam Ficial, Jean-Christophe Pignon, Abdallah Flaifel, Robert J. Motzer, David F. McDermott, Toni K. Choueiri, Sabina Signoretti, Nizar M. Tannir
Rok vydání: 2023
DOI: 10.1158/1078-0432.22478162.v1
Popis: ORR in patients with sRCC and I/P-risk disease, per IRRC, by central or local pathology review.
Databáze: OpenAIRE